Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrimycin plus polymyxin for carbapenem-resistant gram-negative pulmonary infection
ChiCTR2100050817Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carrimycin in pulmonary infection, pneumonia and Gram-negative bacterial infection (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Bacterial clearance rate after 14 days and Target enrollment completed within 6 months. Started Sep 2021; status: recruiting.
02
Drugs
carrimycin
03
Conditions
pulmonary infectionpneumoniaGram-negative bacterial infection
Beyond the preview
Go deeper on ChiCTR2100050817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050817.